Verified news and analysis on AI pharma — clinical milestones, financing, partnerships, and regulation. Updated regularly.
Isomorphic Labs, the AI drug discovery spinout from Google DeepMind, is reportedly in early funding talks targeting a massive valuation. The company is aiming for its first clinical trials, underscoring the significant investor confidence in AI-driven pharmaceutical development.
AI-powered drug discovery company Iambic Therapeutics is planning an initial public offering to raise capital for its cancer drug pipeline. The proceeds will be used to fund clinical trials, marking a significant step for AI-native biotechs entering the public market.
Insilico Medicine has nominated ISM1354, a generative AI-designed preclinical candidate targeting GIPR, for the treatment of obesity, type 2 diabetes, and related metabolic diseases. The compound has shown potential for expansion into cardiovascular applications and was well-tolerated in early toxicology studies.
XtalPi is advancing an AI-driven hair loss candidate into IND-enabling studies after it matched existing hair-growth benchmarks at a fraction of the concentration of standard topical minoxidil. The company leverages artificial intelligence to accelerate the discovery and development of novel therapeutic candidates.
AI drug discovery company BigHat has secured a $75 million financing round led by Premji Invest. The funding supports the clinical development of its AI-designed drug candidates, with one program already reaching Phase 1 trials.
Hansa Biopharma is deploying Cradle's end-to-end AI platform to develop novel immunomodulatory therapies for autoimmune diseases. The collaboration reflects the company's strategic investment in AI-powered drug discovery to build its next-generation pipeline.
Insilico Medicine, a clinical-stage drug discovery company powered by generative AI, has announced the nomination of ISM1354. This next-generation small molecule GIPR antagonist represents a new milestone in AI-driven drug development, pointing the way for further optimization.
Genentech's head of research and early development announced the company's goal to achieve AI independence in drug development. The pharmaceutical giant is establishing a self-sustaining AI laboratory to accelerate new drug discovery and reduce traditional R&D friction.
Insilico Medicine has dosed the first patient in the GENESIS-IPF-3 trial, marking a major milestone as the world's first Phase III clinical trial for a generative AI-designed innovative drug. This development underscores the progression of AI-discovered compounds into late-stage clinical validation.
MindRank has partnered with 3SBio subsidiaries to commercialize an AI-designed oral small-molecule GLP-1 receptor agonist. This collaboration highlights the growing commercial interest in AI-discovered therapeutics for metabolic diseases in the Chinese market.